News Focus
News Focus
icon url

skitahoe

02/12/22 10:56 PM

#443664 RE: HappyLibrarian #443651

HL,

Is it possible that DCVax-Prostate, Brain, Lung, etc. are all actually the same product, made from the Lysate of the cancer and in fact all can be defined by DCVax-L.

DCVax-Direct is different as it doesn't require the lysate from the tumor, it's injected into the tumor directly and creates the vaccine from within.

I know currently the intent is to use Direct on inoperable tumors, and that's the way the trials should be run. If in fact its benefits are seen in that venue, I question if it's use prior to surgery on operable tumors shouldn't be considered. As I see it, the biggest benefit of such treatment would be getting vaccine into the mets before the tumor is removed. It's the unseen and inoperable mets that later create new tumors. While creating DCVax-L from the tumor will certainly be of benefit, I would hope the benefit could be even greater if DCVax-Direct were injected some period of time before the tumor was surgically removed.

I could certainly be wrong about this if the presents of DCVax-Direct within the tumor detracted in some way from the Lysate used to create the DCVax-L. I welcome the thoughts of others on this matter.

Gary
icon url

Doc logic

02/12/22 11:54 PM

#443665 RE: HappyLibrarian #443651

HappyLibrarian,

That name DCVax-Lung came out supposedly by accident for the original combo trial with BMY on the trial registry as I recall and I figured it might be an upgrade of some sort. Supposedly the Lung name was meant to be L for lysate but was printed up as Lung instead. Not a really big deal but I took it as a hint because I believe improvements are always in the works outside of the Phase 3 L trial and at the right time those improvements will be made known. That’s the beauty of this tech, it keeps getting better over time as activation/maturation improves and other processes, adjuvants and combos, when needed, get moved into position without drawing unwanted attention, to reach a larger and more diverse patient population. Getting positioned to take advantage of new guidance and programs with all that has been learned will propel all future applications forward at warp speed compared to past NWBO speed and this set up has all been happening behind the scenes because NWBO has remained silent about their strategy and advances with the science making it much more difficult for others to catch up. They have left clues and a deep dive into the science reveals others that they would want to be moving towards without drawing attention. One day in the not too distant future I believe you will be very pleasantly surprised, or maybe not, that NWBO’s “tardiness” was really “preparedness” for the many next steps. Best wishes.